Alembic Pharmaceuticals Limited
APLLTD · Capital Goods · NSE
₹747
Current Market Price
Fair Value (DCF)
₹921
Margin of Safety
+23.3%
Updated just now
YieldIQ Score
52/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
28%
ROE
11.2%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.15 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.7%
Return on capital employed
EV / EBITDA
14.7×
Enterprise multiple
Debt / EBITDA
1.1×
Leverage vs earnings
Interest Coverage
10.0×
EBIT covers interest
Current Ratio
1.69×
Short-term liquidity
Asset Turnover
0.89×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
5.1%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹747.45
Bear case
₹542.6
MoS -37.8%
Base case
₹921.47
MoS +18.9%
Bull case
₹1,260.25
MoS +40.7%
Ratio Trends
APLLTD · last 8 annual periods
ROE
11.2%
ROCE
16.5%
Operating Margin
—
Debt / Equity
0.24×
PE
63.9×
EV / EBITDA
15.2×
Historical Financials
APLLTD · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹5393 Cr | ₹5306 Cr | ₹1406 Cr | ₹1517 Cr | ₹6540 Cr | +4.9% |
| EBITDA | — | ₹930 Cr | ₹680 Cr | ₹961 Cr | ₹1065 Cr | +3.4% |
| EBIT | ₹1384 Cr | ₹638 Cr | ₹139 Cr | ₹194 Cr | — | -38.8% |
| PAT | ₹1147 Cr | ₹521 Cr | ₹153 Cr | ₹178 Cr | ₹583 Cr | -15.5% |
| EPS (diluted) | ₹60.81 | ₹27.76 | ₹7.76 | ₹9.07 | — | -37.9% |
| CFO | ₹1463 Cr | ₹552 Cr | ₹724 Cr | ₹803 Cr | ₹88.0 Cr | -50.5% |
| CapEx | — | — | — | — | ₹-564 Cr | — |
| FCF | — | — | — | — | ₹-476 Cr | — |
| Total Assets | — | ₹7122 Cr | ₹6183 Cr | ₹6446 Cr | ₹7773 Cr | +2.2% |
| Total Debt | — | — | ₹636 Cr | ₹430 Cr | ₹1258 Cr | +18.6% |
| Shareholders' Equity | — | — | ₹4370 Cr | ₹4818 Cr | ₹5190 Cr | +4.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
APLLTD vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| COHANCE COHANCE | — | — | Pending | 14.6% | — |
| JUBLPHARMA JUBLPHARMA | — | — | Pending | 13.5% | — |
| GRANULES Granules India Limited | +2.0% | 51 | Fairly valued | 13.5% | — |
| CAPLIPOINT CAPLIPOINT | — | — | Pending | 18.6% | — |
| ALIVUS ALIVUS | — | — | Pending | 17.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹54.00/sh
Last payout
2025-07-29
₹11.00
Peak payout
₹14.00
Trailing yield
1.47%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Alembic Pharmaceuticals Limited (APLLTD.NS) trades at 747.45 vs a model fair value of 921.47, a gap of 23.3%. Piotroski F-score: 5/9. Moa...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of APLLTD →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for APLLTD →
Compare
Head-to-head with peers
Compare APLLTD side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse APLLTDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.